Terms: = Lung cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Treatment
1025 results:
1. Targeted inhibition of the PI3K/AKT/mtor pathway by (+)-anthrabenzoxocinone induces cell cycle arrest, apoptosis, and autophagy in non-small cell lung cancer.
Li XQ; Cheng XJ; Wu J; Wu KF; Liu T
Cell Mol Biol Lett; 2024 Apr; 29(1):58. PubMed ID: 38649803
[TBL] [Abstract] [Full Text] [Related]
2.
Miao X; Jiang P; Zhang X; Li X; Wu Z; Jiang Y; Liu H; Xie W; Li X; Shi B; Cai J; Gong W
Microbiol Spectr; 2024 May; 12(5):e0183923. PubMed ID: 38564670
[TBL] [Abstract] [Full Text] [Related]
3. NDRG2 acts as a negative regulator of the progression of small-cell lung cancer through the modulation of the PTEN-AKT-mtor signalling cascade.
Ma Z; Ma Y; Feng J; Xu Z; Cheng C; Qin J; Li S; Jiang J; Kong R
Toxicol Appl Pharmacol; 2024 Apr; 485():116915. PubMed ID: 38537875
[TBL] [Abstract] [Full Text] [Related]
4. Lymphangioleiomyomatosis in patients with tuberous sclerosis: a national centre audit.
Johnson J; Somerfield W; Johnson SR
Orphanet J Rare Dis; 2024 Mar; 19(1):137. PubMed ID: 38532450
[TBL] [Abstract] [Full Text] [Related]
5. Recent advances in the therapeutic potential of nobiletin against respiratory diseases.
Qin Y; Yang J; Li H; Li J
Phytomedicine; 2024 Jun; 128():155506. PubMed ID: 38522319
[TBL] [Abstract] [Full Text] [Related]
6. Scutellarin, a flavonoid compound from Scutellaria barbata, suppresses growth of breast cancer stem cells in vitro and in tumor-bearing mice.
Ma H; Yue GG; Lee JK; Gao S; Yuen KK; Cheng W; Li X; Lau CB
Phytomedicine; 2024 Jun; 128():155418. PubMed ID: 38518647
[TBL] [Abstract] [Full Text] [Related]
7. TMEM120B strengthens breast cancer cell stemness and accelerates chemotherapy resistance via β1-integrin/FAK-TAZ-mtor signaling axis by binding to MYH9.
Hu R; Cao Y; Wang Y; Zhao T; Yang K; Fan M; Guan M; Hou Y; Ying J; Ma X; Deng N; Sun X; Zhang Y; Zhang X
Breast Cancer Res; 2024 Mar; 26(1):48. PubMed ID: 38504374
[TBL] [Abstract] [Full Text] [Related]
8. Corynoxine triggers cell death via activating PP2A and regulating AKT-mtor/GSK3β axes in NSCLC.
Hou G; Hu W; Sang Y; Gan X; Xu H; Hu Q; Cao X
Biochem Pharmacol; 2024 Apr; 222():116110. PubMed ID: 38460908
[TBL] [Abstract] [Full Text] [Related]
9. PI3Kα inhibitor GNE-493 triggers antitumor immunity in murine lung cancer by inducing immunogenic cell death and activating T cells.
Xue X; Ye G; Zhang L; Zhu X; Liu Q; Rui G; Geng G; Lin Y; Chen X
Int Immunopharmacol; 2024 Mar; 130():111747. PubMed ID: 38442576
[TBL] [Abstract] [Full Text] [Related]
10. PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities.
Liu X; Mei W; Zhang P; Zeng C
Pharmacol Res; 2024 Apr; 202():107123. PubMed ID: 38432445
[TBL] [Abstract] [Full Text] [Related]
11. Synergistic anti-tumor effects of lenalidomide and gefitinib by upregulating ADRB2 and inactivating the mtor/PI3K/AKT signaling pathway in lung adenocarcinoma.
Zhou S; Deng M; Bian X; Shi J; Liang R; Tao M
Cell Mol Biol (Noisy-le-grand); 2024 Feb; 70(2):120-127. PubMed ID: 38430032
[TBL] [Abstract] [Full Text] [Related]
12. NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy.
Raskova Kafkova L; Mierzwicka JM; Chakraborty P; Jakubec P; Fischer O; Skarda J; Maly P; Raska M
Front Immunol; 2024; 15():1342086. PubMed ID: 38384472
[TBL] [Abstract] [Full Text] [Related]
13. Synergism of non-thermal plasma and low concentration RSL3 triggers ferroptosis via promoting xCT lysosomal degradation through ROS/AMPK/mtor axis in lung cancer cells.
Peng S; Chen G; Yu KN; Feng Y; Zhao L; Yang M; Cao W; Almahi WAA; Sun M; Xu Y; Zhao Y; Cheng C; Zhu F; Han W
Cell Commun Signal; 2024 Feb; 22(1):112. PubMed ID: 38347507
[TBL] [Abstract] [Full Text] [Related]
14. UPP1 promotes lung adenocarcinoma progression through the induction of an immunosuppressive microenvironment.
Li Y; Jiang M; Aye L; Luo L; Zhang Y; Xu F; Wei Y; Peng D; He X; Gu J; Yu X; Li G; Ge D; Lu C
Nat Commun; 2024 Feb; 15(1):1200. PubMed ID: 38331898
[TBL] [Abstract] [Full Text] [Related]
15. CD36 inhibition reduces non-small-cell lung cancer development through AKT-mtor pathway.
Liu H; Guo W; Wang T; Cao P; Zou T; Peng Y; Yan T; Liao C; Li Q; Duan Y; Han J; Zhang B; Chen Y; Zhao D; Yang X
Cell Biol Toxicol; 2024 Feb; 40(1):10. PubMed ID: 38319449
[TBL] [Abstract] [Full Text] [Related]
16. Plin2 inhibits autophagy via activating AKT/mtor pathway in non-small cell lung cancer.
Wang Y; Hu Y; Xu R; Jin X; Jiao W
Exp Cell Res; 2024 Feb; 435(2):113955. PubMed ID: 38301990
[TBL] [Abstract] [Full Text] [Related]
17. Unveiling the potential effects of resveratrol in lung cancer treatment: Mechanisms and nanoparticle-based drug delivery strategies.
Najafiyan B; Bokaii Hosseini Z; Esmaelian S; Firuzpour F; Rahimipour Anaraki S; Kalantari L; Hheidari A; Mesgari H; Nabi-Afjadi M
Biomed Pharmacother; 2024 Mar; 172():116207. PubMed ID: 38295754
[TBL] [Abstract] [Full Text] [Related]
18. Ginsenoside Rg5 induces NSCLC cell apoptosis and autophagy through PI3K/Akt/mtor signaling pathway.
Zhang C; Jin Y
Hum Exp Toxicol; 2024; 43():9603271241229140. PubMed ID: 38289222
[TBL] [Abstract] [Full Text] [Related]
19. Xie-Bai-San increases NSCLC cells sensitivity to gefitinib by inhibiting Beclin-1 mediated autophagosome formation.
Ma C; Zhang X; Mo X; Yu Y; Xiao Z; Wu J; Ding L; Lei C; Zhu Y; Zhang H
Phytomedicine; 2024 Mar; 125():155351. PubMed ID: 38232540
[TBL] [Abstract] [Full Text] [Related]
20. Discovery of Novel Aminobutanoic Acid-Based ASCT2 Inhibitors for the treatment of Non-Small-Cell lung cancer.
Qin L; Cheng X; Wang S; Gong G; Su H; Huang H; Chen T; Damdinjav D; Dorjsuren B; Li Z; Qiu Z; Bian J
J Med Chem; 2024 Jan; 67(2):988-1007. PubMed ID: 38217503
[TBL] [Abstract] [Full Text] [Related]
[Next]
